Cerebrospinal fluid (CSF) analysis is a well-established method to support a clinical diagnosis of Alzheimer disease (AD), with validated and clinically approved biomarkers for β-amyloid (Aβ) pathology, phosphorylated tau (p-tau), and neurodegeneration. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.